首页> 外文期刊>Drug safety: An international journal of medical toxicology and drug experience >Challenges and Opportunities for the Traceability of (Biological) Medicinal Products
【24h】

Challenges and Opportunities for the Traceability of (Biological) Medicinal Products

机译:(生物)药品可追溯性的挑战和机遇

获取原文
获取原文并翻译 | 示例
           

摘要

This article provides an overview of the current situation regarding the traceability of medicinal products, with a focus on drug safety and biologics. Limited traceability of biologics, in particular with regard to the batch number, is associated with incomplete recording of exposure information in clinical practice. The current pharmaceutical barcode standards in the EU do not support the automatic recording of dynamic product information, such as batch numbers and expiry dates, by means of electronic barcode scanning in clinical practice. New barcode requirements, such as the 2D DataMatrix with encoded batch numbers and expiry dates, provided on both the primary and the secondary package, can facilitate routine barcode scanning at all points in the supply chain in different healthcare settings. To build a full track-and-trace system for medicines with electronic capture of relevant exposure information, alignment with other topics, such as the Falsified Medicines Directive and initiatives to reduce medication errors, is needed to increase the buy-in from all stakeholders and to solve multiple issues with a joint effort.
机译:本文概述了目前关于药品可追溯性的情况,重点是药物安全和生物学。生物制剂的可追溯性有限,特别是关于批量编号,与临床实践中的曝光信息不完全记录相关。欧盟目前的药物条形码标准不支持通过在临床实践中的电子条形码扫描来自动记录动态产品信息,例如批号和到期日期。新的条形码要求(例如主要和辅助程序包中提供的2D DataMatrix),如主包和辅助包,可以促进不同医疗设置中供应链中所有点的例行条形码扫描。为了为具有相关曝光信息的电子捕获的药物构建完整的轨迹和跟踪系统,需要与其他主题的对齐,例如伪造的药物指令和减少药物错误的措施,以增加所有利益相关者的买入以共同努力解决多个问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号